Evidence map›Paper›PMID 29920276›Full record

ArticleDevelopmental cell2018

Twist1 Activation in Muscle Progenitor Cells Causes Muscle Loss Akin to Cancer Cachexia.

Parash Parajuli, Santosh Kumar, Audrey Loumaye, Purba Singh, Sailaja Eragamreddy, Thien Ly Nguyen, Seval Ozkan, Mohammed S Razzaque, Céline Prunier, Jean-Paul Thissen and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Developmental cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Parash ParajuliCancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Santosh KumarCancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Audrey LoumayeEndocrinology, Diabetology, and Nutrition Department, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
Purba SinghCancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Sailaja EragamreddyCancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Thien Ly NguyenCancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Seval OzkanCancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Mohammed S RazzaqueDepartment of Applied Oral Sciences, The Forsyth Institute, Harvard School of Dental Medicine Affiliate, Cambridge, MA 02142, USA.
Céline PrunierSorbonne Universités, UPMC Univ Paris 06, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris 75012, France.
Jean-Paul ThissenEndocrinology, Diabetology, and Nutrition Department, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
Azeddine AtfiCancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA; Sorbonne Universités, UPMC Univ Paris 06, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris 75012, France. Electronic address: aatfi@umc.edu.
University of Mississippi Medical Center · USUCLouvain · BECentre de Recherche Saint-Antoine · FRSorbonne Université · FR

Funding

Targeting the TGIF/Twist1 network in osteosarcomaR01CA210911 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI ATFI, AZEDDINE · 2017 to 2021
$1.8M
Role of TGIF in Wnt-Induced Bone FormationR01AR059070 · NIAMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI ATFI, AZEDDINE · 2010 to 2014
$1.7M
NCI NIH HHS R01 CA210911NIAMS NIH HHS R01 AR059070
6 · The paper itself

Abstract

Cancer cachexia is characterized by extreme skeletal muscle loss that results in high morbidity and mortality. The incidence of cachexia varies among tumor types, being lowest in sarcomas, whereas 90% of pancreatic ductal adenocarcinoma (PDAC) patients experience severe weight loss. How these tumors trigger muscle depletion is still unfolding. Serendipitously, we found that overexpression of Twist1 in mouse muscle progenitor cells, either constitutively during development or inducibly in adult animals, caused severe muscle atrophy with features reminiscent of cachexia. Using several genetic mouse models of PDAC, we detected a marked increase in Twist1 expression in muscle undergoing cachexia. In cancer patients, elevated levels of Twist1 are associated with greater degrees of muscle wasting. Finally, both genetic and pharmacological inactivation of Twist1 in muscle progenitor cells afforded substantial protection against cancer-mediated cachexia, which translated into meaningful survival benefits, implicating Twist1 as a possible target for attenuating muscle cachexia in cancer patients.

Indexed as

AnimalsCachexiaCell Line, TumorColorectal NeoplasmsHEK293 CellsHumansLung NeoplasmsMaleMiceMice, Inbred C57BLMuscle CellsMuscle, SkeletalMuscular AtrophyMyoblastsNuclear ProteinsSignal TransductionNuclear ProteinsTWIST1 protein, humanTwist1 protein, mouseTwist-Related Protein 1Activin/Myostatin cytokinescancer cachexiamuscle cachexiamuscle progenitor cellsmuscle protein breakdownpancreatic ductal adenocarcinomaSmad signalingTwist1

Identifiers

PMID29920276
PMCPMC6054474
OpenAlexW2808843677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.